A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of Study Drug A9-3408 in Subjects With Metastatic Melanoma
Alpha-9 Oncology USA Inc.
Alpha-9 Oncology USA Inc.
MonTa Biosciences ApS
Replimune Inc.
Fusion Pharmaceuticals Inc.
OncoNano Medicine, Inc.
Modulation Therapeutics, Inc.
TriSalus Life Sciences, Inc.
Novelty Nobility, Inc.
Turnstone Biologics, Corp.
Foghorn Therapeutics Inc.
Perspective Therapeutics
Viralytics
Provectus Pharmaceuticals
Hoffmann-La Roche
Novartis
Opna Bio LLC
Pfizer
Incyte Corporation
Novartis
Iconic Therapeutics, Inc.
Polaris Group
Polaris Group
Ichor Medical Systems Incorporated